Compare Stocks: NVNO, PAVM, HSCS, and LFWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSCS HeartSciences	$3.18 +4.6%	$3.31	$1.63 ▼ $5.25	$14.73M	1.76	270,791 shs	109,299 shs
LFWD Lifeward	$6.49 +0.9%	$7.13	$4.14 ▼ $9.84	$18.21M	0.47	5,627 shs	3,655 shs
NVNO enVVeno Medical	$8.75 +7.0%	$10.03	$7.01 ▼ $30.80	$5.68M	1.29	25,688 shs	36,538 shs
PAVM PAVmed	$2.79 +3.7%	$4.39	$2.58 ▼ $28.44	$21.51M	0.69	27,737 shs	12,151 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSCS HeartSciences	+4.61%	-26.05%	-22.82%	+16.06%	-14.52%
LFWD Lifeward	-1.47%	+10.94%	-10.11%	-22.55%	-34.71%
NVNO enVVeno Medical	+6.97%	+8.02%	-21.56%	-23.94%	-73.88%
PAVM PAVmed	+3.72%	-2.79%	-38.27%	-48.96%	-80.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSCS HeartSciences	$3.18 +4.6%	$3.31	$1.63 ▼ $5.25	$14.73M	1.76	270,791 shs	109,299 shs
LFWD Lifeward	$6.49 +0.9%	$7.13	$4.14 ▼ $9.84	$18.21M	0.47	5,627 shs	3,655 shs
NVNO enVVeno Medical	$8.75 +7.0%	$10.03	$7.01 ▼ $30.80	$5.68M	1.29	25,688 shs	36,538 shs
PAVM PAVmed	$2.79 +3.7%	$4.39	$2.58 ▼ $28.44	$21.51M	0.69	27,737 shs	12,151 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSCS HeartSciences	+4.61%	-26.05%	-22.82%	+16.06%	-14.52%
LFWD Lifeward	-1.47%	+10.94%	-10.11%	-22.55%	-34.71%
NVNO enVVeno Medical	+6.97%	+8.02%	-21.56%	-23.94%	-73.88%
PAVM PAVmed	+3.72%	-2.79%	-38.27%	-48.96%	-80.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSCS HeartSciences	2.00	Hold	$8.00	151.57% Upside
LFWD Lifeward	2.25	Hold	$10.00	54.08% Upside
NVNO enVVeno Medical	2.33	Hold	N/A	N/A
PAVM PAVmed	2.00	Hold	$56.00	1,907.17% Upside

Current Analyst Ratings Breakdown

Latest NVNO, PAVM, HSCS, and LFWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/25/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/24/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/21/2026	HSCS HeartSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/2/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	PAVM PAVmed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/3/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	LFWD Lifeward	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSCS HeartSciences	$4.52K	3,408.70	N/A	N/A	$0.07 per share	45.43
LFWD Lifeward	$22.03M	0.83	N/A	N/A	$5.52 per share	1.18
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$41.38 per share	N/A
PAVM PAVmed	$70K	318.86	N/A	N/A	($2.42) per share	-1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSCS HeartSciences	-$9.14M	-$3.22	N/A	N/A	N/A	N/A	-816.90%	-181.97%	12/21/2026 (Estimated)
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
NVNO enVVeno Medical	-$19.47M	-$19.33	N/A	N/A	N/A	N/A	-62.28%	-56.83%	10/30/2026 (Estimated)
PAVM PAVmed	$400K	-$16.05	N/A	N/A	N/A	-10,794.64%	-126.43%	-25.49%	11/12/2026 (Estimated)

Latest NVNO, PAVM, HSCS, and LFWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/30/2026	N/A	NVNO enVVeno Medical	-$3.27	N/A	N/A	N/A	$2.25 million	N/A
9/14/2026	Q1 2027	HSCS HeartSciences	-$0.72	-$0.86	-$0.14	-$0.86	$0.10 million	$0.00 million
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
7/30/2026	Q2 2026	NVNO enVVeno Medical	-$4.69	-$5.37	-$0.68	-$5.37	$1.00 million	N/A
7/23/2026	Q4 2026	HSCS HeartSciences	-$0.66	-$0.88	-$0.22	-$0.87	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSCS HeartSciences	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
PAVM PAVmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSCS HeartSciences	N/A	0.14	0.07
LFWD Lifeward	0.70	2.33	1.77
NVNO enVVeno Medical	N/A	11.70	11.70
PAVM PAVmed	0.98	1.19	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HSCS HeartSciences	17.24%
LFWD Lifeward	26.76%
NVNO enVVeno Medical	34.71%
PAVM PAVmed	19.93%

Insider Ownership

Company	Insider Ownership
HSCS HeartSciences	4.90%
LFWD Lifeward	1.10%
NVNO enVVeno Medical	15.00%
PAVM PAVmed	13.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HSCS HeartSciences	14	4.84 million	4.61 million	Not Optionable
LFWD Lifeward	81	2.83 million	2.80 million	Optionable
NVNO enVVeno Medical	33	690,000	591,000	No Data
PAVM PAVmed	41	8.00 million	6.93 million	No Data

NVNO, PAVM, HSCS, and LFWD Headlines

Recent News About These Companies

Analyzing InMode (NASDAQ:INMD) and PAVmed (NASDAQ:PAVM)

October 8 at 4:15 AM | americanbankingnews.com

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

September 22, 2026 | prnewswire.com

PAVmed Launches New At-the-Market Equity Offering

September 10, 2026 | tipranks.com

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

PAVmed Inc. Q2 2026 Earnings Call Summary

August 14, 2026 | finance.yahoo.com

PAVmed targets early 2027 Veris 510(k) submission while pursuing PortIO 510(k) pathway

August 14, 2026 | seekingalpha.com

PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

August 14, 2026 | prnewswire.com

PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses

August 13, 2026 | quiverquant.comQ

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

August 5, 2026 | prnewswire.com

Lucid Diagnostics to Participate in Upcoming Investor Conferences

August 4, 2026 | prnewswire.com

PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

July 31, 2026 | prnewswire.com

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

July 30, 2026 | prnewswire.com

PAVmed Shareholders Approve Plan Changes at Annual Meeting

June 24, 2026 | tipranks.com

How The PAVmed (PAVM) Narrative Is Shifting With Reworked Assumptions And A Lower Price Target

June 1, 2026 | finance.yahoo.com

PAVmed Inc. (NASDAQ:PAVM) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ...

May 15, 2026 | finance.yahoo.com

PAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026 | finanznachrichten.de

PAVmed (PAVM) Q4 2025 Earnings Transcript

May 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO, PAVM, HSCS, and LFWD Company Descriptions

HeartSciences NASDAQ:HSCS

$3.18 +0.14 (+4.61%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.16 -0.02 (-0.66%)

As of 10/9/2026 06:32 PM Eastern

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Lifeward NASDAQ:LFWD

$6.49 +0.06 (+0.93%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.48 -0.02 (-0.23%)

As of 10/9/2026 07:30 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

enVVeno Medical NASDAQ:NVNO

$8.75 +0.57 (+6.97%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$8.60 -0.15 (-1.71%)

As of 10/9/2026 07:30 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

PAVmed NASDAQ:PAVM

$2.79 +0.10 (+3.72%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.73 -0.06 (-2.29%)

As of 10/9/2026 04:14 PM Eastern

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVNO, PAVM, HSCS, and LFWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVNO, PAVM, HSCS, and LFWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVNO, PAVM, HSCS, and LFWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO, PAVM, HSCS, and LFWD Company Descriptions

HeartSciences NASDAQ:HSCS

Lifeward NASDAQ:LFWD

enVVeno Medical NASDAQ:NVNO

PAVmed NASDAQ:PAVM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVNO, PAVM, HSCS, and LFWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVNO, PAVM, HSCS, and LFWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVNO, PAVM, HSCS, and LFWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO, PAVM, HSCS, and LFWD Company Descriptions

HeartSciences NASDAQ:HSCS

Lifeward NASDAQ:LFWD

enVVeno Medical NASDAQ:NVNO

PAVmed NASDAQ:PAVM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools